Welcome to our dedicated page for Maxcyte SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MaxCyte, Inc. (NASDAQ: MXCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol MXCT, MaxCyte uses SEC reports to communicate material events, financial results, capital market actions and governance changes related to its cell-engineering business.
Investors researching MXCT can use this page to review Form 8-K filings that describe significant developments. Recent 8-Ks have covered preliminary unaudited financial results, quarterly earnings releases, an operational restructuring and workforce reduction plan, and leadership changes such as the departure of the chief commercial officer. Another 8-K details MaxCyte’s application to cancel admission of its common stock to trading on the AIM market of the London Stock Exchange, while confirming that its Nasdaq listing remains in place.
MaxCyte’s SEC filings also reference its use of non-GAAP financial measures, including EBITDA, Adjusted EBITDA and Non-GAAP Gross Margin, and explain how management uses these metrics alongside GAAP results. Filings describe the company’s revenue composition, distinguishing between core business revenue and Strategic Platform License (SPL) program-related revenue, and discuss expectations for cost structure and cash resources.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as restructuring costs, expected annualized savings, revenue guidance and capital position. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs and 10-Ks appear promptly, while insider-related disclosures on forms such as Form 4 can be accessed to track reportable transactions by directors and officers. This combination of original filings and AI-generated insights offers a structured way to analyze MaxCyte’s regulatory history and ongoing reporting.
MAXCYTE, INC. President and CEO Masoud Maher received an equity compensation package consisting of stock options and restricted stock units. He was granted an option to buy 600,000 shares of common stock at an exercise price of $0.684 per share, expiring on March 26, 2036. Twenty-five percent of these option shares vest on March 27, 2027, with the rest vesting in 36 equal monthly installments, as long as he continues serving the company. He also received 300,000 restricted stock units, each representing one share of common stock. Twenty-five percent of the RSUs vest on March 27, 2027, and the remaining units vest in three equal annual installments, again contingent on continued service. Following the RSU grant, he holds 475,000 common shares directly. These are compensation-related awards, not open-market purchases or sales.
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026, succeeding Douglas Swirsky following a previously announced transition. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, including roles in investor relations, FP&A, operations and global financial operations.
Ahuja will receive an annual base salary of $450,000, with a target annual cash bonus equal to 50% of base salary. As an inducement to join, he will be granted a nonqualified stock option for 375,000 shares of common stock and a restricted stock unit award covering 187,500 shares. A severance agreement is expected, providing salary continuation, bonus, COBRA coverage and equity vesting acceleration if he is terminated without cause or resigns for good reason, with enhanced benefits in connection with a change of control.
The Vanguard Group amended a Schedule 13G to report zero beneficial ownership of MaxCyte Inc. common stock. The amendment explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries/divisions to report holdings separately. The filing states 0 shares (0%) beneficially owned and is signed March 27, 2026.
MaxCyte, Inc. is a commercial cell engineering company whose ExPERT Flow Electroporation platform underpins next-generation cell and gene therapy research, clinical development and manufacturing. The product family spans five instruments plus proprietary processing assemblies, consumables and GMP electroporation buffer, with more than 857 instruments installed globally.
The company focuses on Strategic Platform Licenses, or SPLs, that pair annual instrument fees with potential precommercial milestones and commercial sales-based payments. MaxCyte reports 33 SPL agreements, 31 active, with 13 clinical programs as of December 31, 2025. These SPLs have potential to generate more than $2 billion, including over $130 million in precommercial milestone opportunities from active clinical programs, of which more than $30 million has been realized so far.
In January 2025, MaxCyte acquired SeQure Dx, adding on- and off-target gene-editing assessment assays and services to support ex vivo and in vivo therapy developers. The company remains loss-making, with a 2025 net loss of $44.6 million and an accumulated deficit of $261.5 million as of December 31, 2025. Research and development expenses were $20.8 million in 2025 and $22.2 million in 2024, reflecting continued investment in platform innovation. Management highlights dependence on biopharmaceutical R&D spending, milestone timing under SPLs, competition from other non-viral delivery and electroporation providers, and regulatory and data-privacy obligations as key risks.
MaxCyte reported weaker 2025 results and trimmed its outlook for 2026. Full year 2025 revenue was $33.0 million, down from $38.6 million, with total core revenue falling to $29.6 million. The company posted a 2025 net loss of $44.6 million and an EBITDA loss of $47.6 million, including restructuring and goodwill impairment charges.
Fourth quarter 2025 revenue was $7.3 million, a 16% decline year over year, while core revenue dropped 22%. Despite this, gross margin stayed high at 81% for 2025. Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025, and MaxCyte expects to end 2026 with at least $136 million. For 2026, it guides to total revenue of $30–32 million, including core revenue of $25–27 million and $5 million from Strategic Platform License (SPL) programs, reflecting continued customer headwinds.
MaxCyte, Inc. reported that Nasdaq notified the company its common stock no longer meets the Nasdaq Global Select Market’s minimum bid price requirement because the closing bid has been below $1.00 per share for 30 consecutive trading days. The stock remains listed for now and continues to trade on Nasdaq.
MaxCyte has 180 calendar days, until September 14, 2026, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. If it fails to do so, the company may seek an additional 180-day period by transferring to the Nasdaq Capital Market, subject to meeting other listing standards. Nasdaq could ultimately move to delist the shares, and there is no assurance MaxCyte will regain or maintain compliance.
MAXCYTE, INC. Chief Financial Officer Douglas J. Swirsky reported an open-market sale of 10,142 shares of common stock at a weighted average price of $0.815 per share. The shares were sold automatically to cover tax withholding due upon the vesting of previously granted RSUs, and are described as a non-discretionary “sale to cover” transaction. After this sale, Swirsky directly holds 151,669 shares of MaxCyte common stock.
MaxCyte, Inc. received an updated ownership report from Cadian Capital affiliates and Eric Bannasch. As of December 31, 2025, they may have been deemed to beneficially own 3,683,052 shares of MaxCyte common stock, representing approximately 3.5% of the company’s outstanding shares.
The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, which are advisory clients of Cadian Capital Management, LP. The reporting parties state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MaxCyte.
Capricorn Fund Managers Limited has filed a Schedule 13G reporting beneficial ownership of 8,200,000 shares of MaxCyte, Inc. common stock, representing 7.7% of the class as of the event date 01/30/2026.
Capricorn reports sole voting power over these 8,200,000 shares, with no shared voting power and no sole or shared dispositive power. The position is certified as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of MaxCyte. The filer is a United Kingdom entity acting as a foreign investment adviser under a regulatory regime it states is substantially comparable to that of a functionally equivalent U.S. institution.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 6,997,197 shares of MaxCyte, Inc. common stock, representing 6.6% of the class as of 12/31/2025.
BlackRock reports sole voting power over 6,901,491 shares and sole dispositive power over 6,997,197 shares, with no shared voting or dispositive power. The filing explains that the position reflects securities beneficially owned by certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, with no single person holding more than five percent of the outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MaxCyte.